Clinical Trials
3
Active:0
Completed:3
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)A Phase I Extension Trial of Repeated Infusions of ISF35
Phase 1
Completed
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2008-10-31
- Lead Sponsor
- Memgen, LLC
- Target Recruit Count
- 4
- Registration Number
- NCT00783588
- Locations
- 🇺🇸
University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)
Phase 1
Completed
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2008-10-24
- Lead Sponsor
- Memgen, LLC
- Target Recruit Count
- 9
- Registration Number
- NCT00779883
- Locations
- 🇺🇸
University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL
Phase 1
Completed
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- Memgen, LLC
- Target Recruit Count
- 13
- Registration Number
- NCT00772486
- Locations
- 🇺🇸
University of California, San Diego Moores Cancer Center, San Diego, California, United States
News
Pipeline Advances in Head and Neck Cancer Treatment: Over 100 Drugs in Development for 2025
DelveInsight's latest report reveals a robust pipeline with over 80 companies developing 100+ drug candidates for head and neck cancer, highlighting significant research momentum in this therapeutic area.